2014 Rhabdomyosarcoma Pico-course

It was an exciting week for the participants of the 2014 Rhabdomyosarcoma Pico-course.  The

goal was to evaluate progress 2000-2014 in cooperative group clinical trials of new agents for rhabdomyosarcoma.  The students concluded that in such trials >525 patients had been planned, at a potential overall cost well exceeding $4.7M (not counting the expense of the drugs themselves).  Many of the results of these clinical trials are still pending.  That said, this was a very hardworking group of students who really came together for a high-level project and did a terrific job.  

Muscle Differentiation as Rhabdomyosarcoma Therapy

Matthew from our lab wrote this commentary in Cancer Cell, which frames the question of how soon myo-differentiation therapy will be feasible for childhood muscle cancer.  The commentary discusses the article here.  Graphic illustration by Nick Escobar.